The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.
Derington CG, Bress AP, Herrick JS, Fan W, Wong ND, Andrade KE, Johnson J, Philip S, Abrahamson D, Jiao L, Bhatt DL, Weintraub WS.
Derington CG, et al. Among authors: abrahamson d.
Am J Prev Cardiol. 2022 Apr 28;10:100345. doi: 10.1016/j.ajpc.2022.100345. eCollection 2022 Jun.
Am J Prev Cardiol. 2022.
PMID: 35574517
Free PMC article.